Switching from ergot to nonergot dopamine agonists in Parkinson's disease: A clinical series and five-drug dose conversion table

被引：88

作者：

Grosset, K

Needleman, F

Macphee, G

Grosset, D ^{[1
]}

机构：

[1] So Gen Hosp, Dept Neurol, Inst Neurol Sci, Glasgow G51 4TF, Lanark, Scotland

[2] So Gen Hosp, Dept Clin Pharm, Glasgow, Lanark, Scotland

来源：

MOVEMENT DISORDERS | 2004年 / 19卷 / 11期

关键词：

Parkinson's disease; dopamine agonists; ergot;

D O I：

10.1002/mds.20210

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Of 99 patients on ergot-derived dopamine agonists informed about possible long-term side effects, switching to a nonergot was undertaken in 88 (89%). There were adverse events in 26%. After 11 months, 82% were on their switch agonist and 93% were on any agonist. Switching dopamine agonists is feasible in this population. (C) 2004 Movement Disorder Society.

引用

页码：1370 / 1374

页数：5

共 24 条

[1]

Benard A, 1996, REV MAL RESPIR, V13, P227

[2] An overnight switch to ropinirole therapy in patients with Parkinson's disease [J].

Canesi, M ;

Antonini, A ;

Mariani, CB ;

Tesei, S ;

Zecchinelli, AL ;

Barichella, M ;

Pezzoli, G .

JOURNAL OF NEURAL TRANSMISSION, 1999, 106 (9-10) :925-929

[3]

*EC PHARM COMM, 1998, GUID REL LAB PACK LE

[4] Cabergoline in Parkinson's disease complicated by motor fluctuations [J].

Geminiani, G ;

Fetoni, V ;

Genitrini, S ;

Giovannini, P ;

Tamma, F ;

Caraceni, T .

MOVEMENT DISORDERS, 1996, 11 (05) :495-500

[5]

Giménez-Roldán S, 2001, CLIN NEUROPHARMACOL, V24, P346

[6] Switching dopamine agonists in advanced Parkinson's disease - Is rapid titration preferable to slow? [J].

Goetz, CG ;

Blasucci, L ;

Stebbins, GT .

NEUROLOGY, 1999, 52 (06) :1227-1229

[7] AGONIST SUBSTITUTION IN ADVANCED PARKINSONS-DISEASE [J].

GOETZ, CG ;

SHANNON, KM ;

TANNER, CM ;

CARROLL, VS ;

KLAWANS, HL .

NEUROLOGY, 1989, 39 (08) :1121-1122

[8] Switching from pergolide to pramipexole in patients with Parkinson's disease [J].

Hanna, PA ;

Ratkos, L ;

Ondo, WG ;

Jankovic, J .

JOURNAL OF NEURAL TRANSMISSION, 2001, 108 (01) :63-70

[9] Ropinirole and pramipexole, the new agonists [J].

Hobson, DE ;

Pourcher, E ;

Martin, WRW .

CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1999, 26 :S27-S33

[10] Pramipexole vs levodopa as initial treatment for Parkinson disease - A randomized controlled trial [J].

Holloway, R ;

Shoulson, I ;

Kieburtz, K ;

McDermott, M ;

Tariot, P ;

Kamp, C ;

Day, D ;

Shinaman, A ;

Fahn, S ;

Lang, A ;

Marek, K ;

Seibyl, J ;

Weiner, W ;

Welsh, M ;

Pahwa, R ;

Coe, S ;

Barclay, L ;

Sutherland, L ;

Hildebrand, K ;

Hubble, J ;

Weeks, C ;

LeWitt, P ;

Miyasaki, J ;

Duff, J ;

Sime, E ;

Suchowersky, O ;

Stacy, M ;

Kurth, M ;

Brewer, M ;

Harrigan, M ;

Russell, DS ;

Fussell, B ;

Ford, B ;

Dillon, S ;

Hammerstad, J ;

Stone, C ;

Riley, D ;

Rainey, P ;

Standaert, D ;

Tennis, M ;

Wooten, F ;

Rost-Ruffner, E ;

Factor, S ;

Brown, D ;

Jankovic, J ;

Atassi, F ;

Kurlan, R ;

Gardiner, I ;

Panisset, M ;

Amyot, D .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (15) :1931-1938

← 1 2 3 →